Results 61 to 70 of about 5,463 (146)

Obinutuzumab in Refractory Membranous Nephropathy: A Case Series

Kidney Medicine
Rationale & Objective: Membranous nephropathy (MN), recognized as an autoimmune kidney disease, responds well to anti-CD20 monoclonal antibodies. Obinutuzumab, a type Ⅱ humanized anti-CD20 and immunoglobulin G1 Fc-optimized monoclonal antibody, when ...
Yuxin Lin, Quan Han, Liangliang Chen, Yaomin Wang, Pingping Ren, Guangjun Liu, Lan Lan, Xin Lei, Jianghua Chen, Fei Han   +9 more
doaj   +1 more source

Clinical application of obinutuzumab for treating chronic lymphocytic leukemia

Drug Design, Development and Therapy, 2019
Chunyan Luan, Baoan ChenDepartment of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu Province 210009, People’s Republic of ChinaCorrespondence: Baoan ChenDepartment of Hematology and Oncology ...
Luan C, Chen B
doaj  

Combining Obinutuzumab With Radiation for Refractory DLBCL: Retrospective Safety and Efficacy Analysis

Advances in Radiation Oncology
Purpose: Approximately 30% of patients with diffuse large B cell lymphoma (DLBCL) will develop relapsed or treatment-refractory disease after primary chemotherapy.
Brett A. Morris, MD, PhD, Emily C. Merfeld, MD, Adam R. Burr, MD, PhD, Kristin A. Bradley, MD, Christopher D. Fletcher, MD   +4 more
doaj   +1 more source

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

Pharmacogenomics and Personalized Medicine, 2014
Lukáš Smolej 4th Department of Internal Medicine – Hematology, University Hospital Hradec Králové and Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech
Smolej L
doaj  

Characterization of anti-canine CD20 antibody 4E1-7-B_f and comparison with commercially available anti-human CD20 antibodies.

PLoS ONE
This study characterizes the previously reported anti-canine CD20 antibody 4E1-7-B_f and compares this with commercially available anti-human CD20 antibodies, rituximab and an obinutuzumab biosimilar.
Takuya Mizuno, Yukinari Kato, Toshihiro Tsukui, Masaya Igase   +3 more
doaj   +1 more source

Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases

Biomedicines
Background/Objectives: Obinutuzumab was approved for front-line treatment of chronic lymphocytic leukemia in combination with chlorambucil pulses administered every 2 wks.
Igor Aurer, Ozren Jakšić, Sandra Bašić-Kinda, Karla Mišura-Jakobac, Jasminka Sinčić-Petričević, Sabina Novaković-Coha, Davor Galušić, Hrvoje Holik, Toni Valković, Dubravka Županić-Krmek, Ida Hude-Dragičević, Vibor Milunović, Vlatko Pejša   +12 more
doaj   +1 more source

The Evolving Role of Obinutuzumab in the Treatment of Splenic Marginal Zone Lymphoma

Case Reports in Hematology
The efficacy of obinutuzumab is established in chronic lymphocytic leukemia and follicular lymphoma. Its role in less frequent B-cell lymphomas is not yet clear.
Maria K. Angelopoulou, Eliana Α. Konstantinou, Ioannis Vasilopoulos, John V. Asimakopoulos, Stavrianna Diavati, Marina P. Siakantaris, Panayiotis Panayiotidis, Theodoros P. Vassilakopoulos, Gerassimos A. Pangalis   +8 more
doaj   +1 more source

Effectiveness and safety of B cell-targeting biologics in the treatment of lupus nephritis: a systematic review and network meta‑analysis

Renal Failure
Objectives To evaluate the effectiveness and safety of different B cell-targeting biological agents combining with standard of care in patients with lupus nephritis (LN).Methods Comprehensive literature searches were conducted using PubMed, Embase, Web ...
Xi Zhao, Si-Qi Yang, Man Li, Yao-Guang Wang   +3 more
doaj   +1 more source

Disseminated Enterovirus Infection in a Patient Affected by Follicular Lymphoma Treated with Obinutuzumab: A Case Report and a Narrative Review of the Literature

Medicina
Background and Objectives: the principal purpose of this literature review is to cluster adults with hematological malignancies after treatment or on maintenance with obinutuzumab who experienced disseminated EV infection to understand clinical ...
Tommaso Lupia, Silvia Corcione, Elena Staffilano, Roberta Bosio, Antonio Curtoni, Alessandro Busca, Francesco Giuseppe De Rosa   +6 more
doaj   +1 more source

Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance

Haematologica
Immunochemotherapy induces long-term response in patients with follicular lymphoma. However, toxicity of chemotherapy remains a relevant challenge. The Bruton’s tyrosine kinase inhibitor ibrutinib has shown significant activity in patients with indolent
Christian Schmidt, Gabriel Scheubeck, Vindi Jurinovic, Martin Sökler, Roswitha Forstpointner, Christian Buske, Andreas Viardot, Ulrich Keller, Ullrich Graeven, Reinhard Marks, Mathias Hänel, Rüdiger Liersch, Jan Dürig, Christiane Pott, Eva Hoster, Michael Unterhalt, Wolfgang Hiddemann   +16 more
doaj   +1 more source